Neovacs SA (FR:ALNEV) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neovacs SA, a biopharmaceutical company, has announced the inclusion of a 100% provision for the value of its claim in its semi-annual accounts, following Pharnext’s judicial liquidation. This precautionary measure was taken due to the non-repayment of bonds by Pharnext, with Neovacs’ financial stability remaining unaffected in terms of cash position and financing capabilities. An upcoming evaluation of Pharnext’s intangible assets could potentially lead to a revaluation in Neovacs’ annual accounts, depending on market authorization outcomes for a Pharnext drug candidate in China.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.